Latest Isis Stories

CARLSBAD, Calif., Aug. 3, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has successfully completed a pre-approval inspection of its manufacturing facility located in Carlsbad, California. As part of the inspection, the European Medicines Agency (EMA) conducted an extensive review of Isis' manufacturing facility and processes and Isis' Good Manufacturing Practices (GMP) Quality systems to ensure product manufactured is of appropriate and...

CARLSBAD, Calif., July 23, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call When: Monday, August 6, 2012 at 11:30 a.m. ET /8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our Web...

CARLSBAD, Calif., July 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012 at 2:00 p.m. ET at the Peninsula Hotel in New York. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the...

CARLSBAD, Calif., June 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2012 Annual Meeting of Stockholders and Open House on Thursday, June 7 at 2:10 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. - 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of April 9,...

CARLSBAD, Calif., May 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5, 2012 at 1:20 p.m. PT at the Terranea Resort in Rancho Palos Verdes, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site,...

CARLSBAD, Calif., May 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012 at 2:30 p.m. ET at the Grand Hyatt in New York, NY. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the...

CARLSBAD, Calif., May 23 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Data from KYNAMRO(TM) presented at EAS 2012 When: Friday, June 1st at 12:00 p.m. ET / 9:00 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at...

CARLSBAD, Calif., May 14, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2012 Annual Meeting of Stockholders and Open House on Thursday, June 7 at 2:10 p.m. Pacific Time in Carlsbad, CA. The agenda for the meeting is as follows:2:00 p.m. - 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of April 9,...

CARLSBAD, Calif., May 9, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Bank of America Merrill Lynch's 2012 Health Care Conference on Tuesday, May 15, 2012 at 2:20 p.m. PT at the Encore at the Wynn in Las Vegas, NV. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A...

CARLSBAD, Calif., May 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $16.2 million for the first quarter of 2012 compared to a pro forma NOL of $13.4 million for the same period in 2011. The Company ended the first quarter of 2012 with nearly $334 million in cash. "Already in 2012, we have had multiple important accomplishments. Our partners at Genzyme submitted the KYNAMRO(TM) new drug application (NDA)...